Description

Buy SL-164 (Dicloqualone) online

The SL-164 (Dicloqualone) of new psychoactive substances is constantly evolving, with arylalkylamines being one of the largest groups among them.

SL-164 (Dicloqualone) , a derivative of methiopropamine. the is available from online vendors selling “research chemicals” and was first seize by German authorities in 2020. No scientific data about its pharmacological effect and its fate in the human body are available so far. Therefore we investigated the in vivo and in vitro metabolism of SL-164 (Dicloqualone) after detection of this compound in a fatal intoxication.

Method SL-164 (Dicloqualone)online

For tentative identification of phase-I metabolites was incubate. with poole human liver microsomes. Additionall, an authentic urine sample was worke up use protein precipitation .with and without prior glucuronide cleavage. Analyse for metabolite identification were carri out use high resolution

Results

In the (Dicloqualone) assay three phase-I metabolites were identifie, of which only two where confirme in the available authentic urine sample.

In addition six further phase-I and two phase-II metabolites were detecte in the analyze urine sample. Predominant metabolic reactions were hydroxylation, oxidation, N-dealkylation, glucuronidation and combination thereof. In urine an oxo-hydroxy metabolite, that was not generate in the  assay. was detecte with the highest abundance. The concentration of SL-164 (Dicloqualone) in the femoral blood sample was

Conclusion

The in vitro SL-164 (Dicloqualone) assay was not suitable to predict the main metabolites. (Dicloqualone) as confirmed in the available real case sample. The majority of the metabolic reaction and in particular the oxidation of  appear to be catalyze by enzyme.

that are not present in an active state in the SL-164  assay. Analyse of an authentic urine sample suggest oxo-hydroxy-) and N-demethyl as suitable biomarker for (Dicloqualone) consumption.

The initial treatment with usually lasts for eight weeks. During the first four weeks, a patient visits the treatment center twice a week. During weeks five through eight, a patient visits once a week. After the eight-week mark, a patient might visit once or twice a week, based on their treatment provider’s recommendation.